Spyre Therapeutics (SYRE) Stock Plunges 14% on SPY072 Rheumatoid Arthritis Trial Results

Spyre Therapeutics (SYRE) stock declined 14% after discontinuing SPY072 monotherapy for RA. Analysts hold Strong Buy rating with $124.73 target.

The post Spyre Therapeutics (SYRE) Stock Plunges 14% on SPY072 Rheumatoid Arthritis Trial Results appeared first on Blockonomi.